Back to List View Graph View

Proprotein convertase subtilisin/kexin type 9 inhibitors

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9 inhibitors, or PCSK9i) are lipid-lowering therapies that target PCSK9, a protein involved in the degradation of the hepatic low-density lipoprotein receptor (LDLR).

Where the papers sit

12 papers from the last 6 months study proprotein convertase subtilisin/kexin type 9 inhibitors directly · updated from PubMed 15 Nov 2026

  • PCSK9 Drug Discovery

    PCSK9-directed work is broadening beyond antibody blockade toward small molecules, natural-product compounds, and gene editing. Structural docking and diacyl-m-phenylenediamine studies seek inhibitors of the PCSK9–LDLR interaction, while flavonoid screens extend the search for lipid-lowering candidates. Variant and knockout studies tie efficacy to LDLR-mediated hepatic LDL uptake, and VERVE-102 tests durable PCSK9 base editing for hypercholesterolemia. A SIRPαD1–αPCSK9 fusion extends PCSK9 targeting into macrophage-mediated tumor clearance, a distinct emerging application.

    7 papers · 58.3%

  • PCSK9 Therapy and Cardiovascular Risk

    PCSK9-directed care is being assessed beyond LDL-C, including lipoprotein(a) reduction and secondary prevention after intracranial atherosclerotic stroke. Alirocumab and inclisiran appear alongside statins as add-on strategies rather than replacements for established therapy. Three-year inclisiran data emphasize sustained LDL-C lowering and treatment persistence in routine practice. Whether these biochemical gains translate into durable cerebrovascular benefit remains an open clinical question.

    3 papers · 25%

  • Others — Inflammation and Lipid Biology

    PCSK9 silencing is being paired with inflammation control in experimental hyperlipidemia therapy. Engineered milk-derived extracellular vesicles and lipid nanoparticles target lipid accumulation while modifying macrophage polarization. Separate pancreatic ductal adenocarcinoma work links sex-associated systemic inflammatory profiles and macrophage responses to survival. The cluster therefore joins mechanistically adjacent but clinically different efforts rather than showing a single therapeutic direction.

    2 papers · 16.7%

NEW DIRECTION

PCSK9 targeting becomes an immunotherapy strategy rather than solely a lipid-lowering intervention

The bispecific SIRPαD1-αPCSK9 fusion protein in tumor macrophages and tumor models 42833217Oct assigns PCSK9 a role outside the set’s lipid-metabolic framework: instead of treating PCSK9 inhibition as a means of improving LDL handling, the study identifies tumor-derived PCSK9 as an adaptive immune-resistance factor that promotes MHC-I degradation, impairs macrophage antigen cross-presentation, and limits CD8+ T-cell priming. Blocking PCSK9 together with CD47–SIRPα signaling therefore reprograms macrophages while restoring adaptive antitumor immunity, extending PCSK9-targeting into combined innate–adaptive cancer immunotherapy.

Papers

The 12 papers from the last 6 months that study proprotein convertase subtilisin/kexin type 9 inhibitors directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

PCSK9 Drug Discovery (7)
  1. Functional impact of PCSK9 variants on LDL uptake in a knockout hepatic model. PloS one · 26 Oct 2026 PMID 42932357
  2. Identification of flavonoids from natural products against hyperlipidaemia through computational approaches. PloS one · 9 Oct 2026 PMID 42853886
  3. Bridging innate and adaptive immunity: A bispecific SIRPαD1-αPCSK9 fusion protein reprograms macrophages for durable tumor clearance. Cell reports. Medicine · 5 Oct 2026 PMID 42833217
  4. Discovery, synthesis, and biological evaluation of N,N'-diacyl-m-phenylenediamine derivatives as novel PCSK9 small-molecule inhibitors. European journal of medicinal chemistry · 4 Aug 2026 PMID 42551132
  5. Discovery of Novel PCSK9-LDLR PPI Inhibitors by a Structural Modification Approach. Drug development research · 13 Jul 2026 PMID 42438221
  6. Plasma proteomics reveal key proteins mediating vascular aging. Life sciences · 16 Jun 2026 PMID 42302926
  7. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia. The New England journal of medicine · 26 May 2026 PMID 42187087
PCSK9 Therapy and Cardiovascular Risk (3)
  1. Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study. Atherosclerosis · 29 Sept 2026 PMID 42809906
  2. Long-term LDL-C lowering and treatment persistence with inclisiran: 3-year follow-up from the German Inclisiran Network. Clinical research in cardiology : official journal of the German Cardiac Society · 28 Sept 2026 PMID 42803952
  3. Add-On PCSK9 Inhibitor Therapy for Acute Stroke Attributable to Intracranial Atherosclerosis: A Randomized Clinical Trial. Journal of the American Heart Association · 9 Sept 2026 PMID 42714476
Others — Inflammation and Lipid Biology (2)
  1. Engineered Milk-Derived Extracellular Vesicles Integrate PCSK9 Silencing and Inflammation Modulation for Hyperlipidemia Therapy. Advanced healthcare materials · 11 Nov 2026 PMID 43012445
  2. Exploring Sex-Associated Systemic Inflammatory Profiles Linked to Macrophage Responses and Survival in Pancreatic Ductal Adenocarcinoma. Journal of proteome research · 6 Nov 2026 PMID 42992895

By study type

Clinical trials (2)
  1. Add-On PCSK9 Inhibitor Therapy for Acute Stroke Attributable to Intracranial Atherosclerosis: A Randomized Clinical Trial. Journal of the American Heart Association · 9 Sept 2026 PMID 42714476
  2. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia. The New England journal of medicine · 26 May 2026 PMID 42187087
Observational studies and case reports (1)
  1. Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study. Atherosclerosis · 29 Sept 2026 PMID 42809906
Human data, design not indexed (5)
  1. Functional impact of PCSK9 variants on LDL uptake in a knockout hepatic model. PloS one · 26 Oct 2026 PMID 42932357
  2. Identification of flavonoids from natural products against hyperlipidaemia through computational approaches. PloS one · 9 Oct 2026 PMID 42853886
  3. Discovery, synthesis, and biological evaluation of N,N'-diacyl-m-phenylenediamine derivatives as novel PCSK9 small-molecule inhibitors. European journal of medicinal chemistry · 4 Aug 2026 PMID 42551132
  4. Discovery of Novel PCSK9-LDLR PPI Inhibitors by a Structural Modification Approach. Drug development research · 13 Jul 2026 PMID 42438221
  5. Plasma proteomics reveal key proteins mediating vascular aging. Life sciences · 16 Jun 2026 PMID 42302926
Preclinical: animal, cell and lab studies (2)
  1. Exploring Sex-Associated Systemic Inflammatory Profiles Linked to Macrophage Responses and Survival in Pancreatic Ductal Adenocarcinoma. Journal of proteome research · 6 Nov 2026 PMID 42992895
  2. Bridging innate and adaptive immunity: A bispecific SIRPαD1-αPCSK9 fusion protein reprograms macrophages for durable tumor clearance. Cell reports. Medicine · 5 Oct 2026 PMID 42833217
Unclassified: not yet indexed with MeSH (2)
  1. Engineered Milk-Derived Extracellular Vesicles Integrate PCSK9 Silencing and Inflammation Modulation for Hyperlipidemia Therapy. Advanced healthcare materials · 11 Nov 2026 PMID 43012445
  2. Long-term LDL-C lowering and treatment persistence with inclisiran: 3-year follow-up from the German Inclisiran Network. Clinical research in cardiology : official journal of the German Cardiac Society · 28 Sept 2026 PMID 42803952